Table 3 Therapeutic profile of people living with hypertension
|  | Total N = 400 | No aTRH N = 325 | aTRH N = 75 | p-value |
|---|---|---|---|---|
Total prescription medication count median (IQR) | 7(4) | 7(3) | 9(3) | < 0.001 |
Total anti-hypertensives median (IQR) | 3(2) | 3(1) | 4(1) | < 0.001 |
Number of anti-hypertensive agents n (%) | Â | Â | Â | Â |
1 agent | 44(11.0) | 44(11.0) | 0(0) | < 0.001 |
2 agents | 100(25.0) | 100(25.0) | 0(0) | < 0.001 |
3 agents | 149(37.3) | 136(41.8) | 13(17.3) | 0.000 |
4 agents | 58(14.5) | 23(7.1) | 35(46.7) | 0.000 |
5 agents | 32(8.0) | 13(4.0) | 19(25.3) | 0.000 |
6 agents | 15(3.8) | 9(2.7) | 6(8.0) | 0.032 |
7 agents | 2(0.5) | 0(0) | 2(2.7) | 0.003 |
Drug class use n (%) | Â | Â | Â | Â |
RAAS Blockers | 294(73.5) | 226(69.5) | 68(90.7) | < 0.001 |
 ACE-I | 267(66.8) | 205(63.1) | 62(82.7) | 0.001 |
 ARB | 27(6.8) | 21(6.5) | 6(8.0) | 0.395 |
Dihydropyridine Calcium Channel Blocker | 272(68.0) | 204(62.8) | 68(90.7) | < 0.001 |
Beta-blocker | 118(29.5) | 74(22.8) | 44(58.6) | < 0.001 |
Alpha blocker | 57(14.3) | 32(9.8) | 25(33.3) | < 0.001 |
Vasodilator | 54(13.5) | 33(10.2) | 21(28.0) | < 0.001 |
Diuretic | Â | Â | Â | Â |
 Thiazide | 225(56.3) | 187(57.5) | 38(50.6) | 0.280 |
 Loop | 124(31.0) | 87(26.8) | 37(49.3) | < 0.001 |
Mineralocorticoid Receptor Antagonist | 43(10.8) | 19(5.8) | 24(32.0) | < 0.001 |
Other drugs | Â | Â | Â | Â |
Lipid-lowering therapy | 327(81.8) | 260(80.0) | 67(89.3) | 0.059 |
Tricyclic anti-depressants | 97(24.3) | 77(23.7) | 20(26.7) | 0.588 |
Non-steroidal anti-inflammatory drugs | 53(13.3) | 44(13.5) | 9(12.0) | 0.723 |
Oral corticosteroids | 11(2.75) | 11(3.4) | 0(0) | 0.230 |